InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct^® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of  steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.

The patent, entitled “Method for Modulating Responsiveness to Steroids” covers a method for enhancing steroid efficacy in steroid-refractory patients afflicted with an inflammatory condition using oligonucleotides with a specific common core sequence. It provides an exclusivity period until June 2027 with the possibility of a 3 to 5-year term extension after market approval. A corresponding European patent was granted in August 2009.  » Read more...

Nanobiotix has appointed Dr. Bernd Muehlenweg, currently Head of Business Development, as a member of the Executive Board in support of the future growth of Nanobiotix.

Bernd Muehlenweg joined Nanobiotix in 2011 as Head of Business Development. From 2001 to 2011, he had been Director Business Development of oncology company WILEX AG (Munich, Germany), where he played a key role in the negotiation and execution of several license and commercialization agreements with pharma companies and in alliance management. He is a member of the Pharma Licensing Club of Germany (Pharmalizenzclub) and of the Pharma Licensing Club of France.

There has been a frenzy about new media and information sources, especially since the emergence of social media like Twitter. Keeping track of all the different media available today is very time-consuming.

Which media do you really use? Do you primarily rely on established trade and financial media? Or are you taking advantage of free online news sources? Do you use Twitter, Facebook, LinkedIn on a regular basis?

We are curious to hear your thoughts!  » Read more...

As every year, akampion will attend some key industry events and conferences. Moreover, we are very happy to contribute to the organization and preparation of two of these events: DVFA Life Science Conference and Deutsche Biotechnologietage (German Biotechnology Industry Event).

Our team will be available at the following conferences in April and May:

• Charité Summit, April 23-24 (Berlin)
• DVFA Life Science Conference, May 8 (Frankfurt)
• Deutsche Biotechnologietage, May 9-10 (Frankfurt)
• Bio€quity, May 15-16 (Frankfurt)

We are looking forward to meeting you and hope to share latest industry insights and thoughts!

- InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer -

Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions to its management team: Pernilla Sandwall has been appointed as Head of Clinical Operations and Thomas Knittel as Chief Medical Officer. Pernilla Sandwall will lead the company’s clinical development team, with the main focus being the ongoing phase III clinical trial of Kappaproct^® in patients with treatment-refractory ulcerative colitis. Thomas Knittel will serve as the company’s lead medical expert and provide leadership in medical and marketing affairs.  » Read more...